Purpose 45% of colon cancer patients are elderly, yet they are often deviated from standard
cancer management. The MOSAIC trial favored FOLFOX over FL with superior oncologic …

Background Colon cancer is common in the elderly, but owing to under representation in
clinical trials, the benefit of standard therapies is uncertain in this age group. We aimed to …

Purpose Although adjuvant chemotherapy (AC) using fluoro-pyrimidine and oxaliplatin (FU+
oxaliplatin) is recommended after curative resection for locally advanced colon cancer …

48 Background: The benefit of adjuvant chemotherapy with oxaliplatin for elderly patients
with colorectal cancer (CRC) remains controversial. Our study could not demonstrate the …

Introduction: Adjuvant chemotherapy improves the prognosis of patients with colorectal
cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin …

Purpose After curative resection of stage II colon cancer, adjuvant chemotherapy with 5-
fluorouracil/leucovorin (FL) or capecitabine is selectively recommended. However, there is …

Background Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in
older patients with stage III colon cancer (CC) produced conflicting results. Patients and …

Objective Elderly patients derive similar benefits from 5-fluorouracil-based adjuvant
chemotherapy in Stage III colon cancer; however, conflicting data exist regarding additional …

Background Fluoropyrimidine plus oxaliplatine treatment has proven an increase in survival
rates in stage III resected CRC. However, clinical trials, mostly do not include population …

Abstract Background Only 50–70% of elderly colon cancer patients could complete the
recommended 6 months of postoperative chemotherapy. It is unknown whether a shorter …